OBESITY PARADOX FOR STROKE IN PATIENTS WITH ATRIAL FIBRILLATION TREATED WITH RIVAROXABAN AND WARFARIN IN THE ROCKET AF TRIAL

被引：2
|
作者：
Balla, Somasekhara R.
Cyr, Derek
Lokhnygina, Yuliya
Becker, Richard
Berkowitz, Scott
Breithardt, Guenter
Califf, Robert
Fox, Keith
Hacke, Werner
Halperin, Jonathan
Hankey, Graeme
Mahaffey, Kenneth
Nessel, Christopher
Piccini, Jonathan
Singer, Daniel
Patel, Manesh
机构：
[1] Halifax Med Specialists, Roanoke Rapids, NC USA
[2] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2014年 / 63卷 / 12期
关键词：
D O I：
10.1016/S0735-1097(14)60371-5
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1180-92
引用
收藏
页码：A371 / A371
页数：1
相关论文
共 50 条
  • [21] Net clinical benefit of rivaroxaban compared with warfarin in atrial fibrillation: Results from ROCKET AF
    Barnett, Adam S.
    Cyr, Derek D.
    Goodman, Shaun G.
    Levitan, Bennett S.
    Yuan, Zhong
    Hankey, Graeme J.
    Singer, Daniel E.
    Becker, Richard C.
    Breithardt, Guenter
    Berkowitz, Scott D.
    Halperin, Jonathan L.
    Hacke, Werner
    Mahaffey, Kenneth W.
    Nessel, Christopher C.
    Fox, Keith A. A.
    Patel, Manesh R.
    Piccini, Jonathan P.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2018, 257 : 78 - 83
  • [22] Efficacy and safety of rivaroxaban versus warfarin in patients from mainland China with nonvalvular atrial fibrillation: A subgroup analysis from the ROCKET AF trial
    Sun, Yihong
    Hu, Dayi
    Stevens, Susanna
    Lokhnygina, Yuliya
    Becker, Richard C.
    Berkowitz, Scott D.
    Breithardt, Gunter
    Hacke, Werner
    Halperin, Jonathan L.
    Hankey, Graeme J.
    Mahaffey, KennethW.
    Nessel, Christopher C.
    Piccini, Jonathan P.
    Singer, Daniel E.
    Fox, Keith A. A.
    Patel, Manesh R.
    THROMBOSIS RESEARCH, 2017, 156 : 184 - 190
  • [23] THROMBOLYTIC THERAPY IN ANTICOAGULATED PATIENTS: CASE SERIES FROM RIVAROXABAN VERSUS WARFARIN IN NONVALVULAR ATRIAL FIBRILLATION (ROCKET AF)
    Chen, Sean
    Hellkamp, Anne
    Becker, Richard
    Berkowitz, Scott
    Breithardt, Guenter
    Fox, Keith
    Hacke, Werner
    Halperin, Jonathan
    Hankey, Graeme
    Mahaffey, Kenneth
    Nessel, Christopher
    Piccini, Jonathan
    Singer, Daniel
    Patel, Manesh
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 446 - 446
  • [24] Management of Major Bleeding Events in Patients Treated With Rivaroxaban Versus Warfarin: Results From the ROCKET AF Trial
    Piccini, Jonathan P.
    Garg, Jyotsna
    Patel, Manesh R.
    Lokhnygina, Yuliya
    Goodman, Shaun G.
    Becker, Richard C.
    Berkowitz, Scott D.
    Breithardt, Gunter
    Hacke, Werner
    Halperin, Jonathan L.
    Hankey, Graeme I.
    Nessel, Christopher C.
    Mahaffey, Kenneth W.
    Singer, Daniel E.
    Califf, Robert M.
    Fox, Keith A.
    CIRCULATION, 2013, 128 (22)
  • [25] Rivaroxaban versus warfarin in Japanese patients with non-valvular atrial fibrillation in relation to hypertension: a subgroup analysis of the J-ROCKET AF trial
    Masayasu Matsumoto
    Masatsugu Hori
    Norio Tanahashi
    Shin-ichi Momomura
    Shinichiro Uchiyama
    Shinya Goto
    Tohru Izumi
    Yukihiro Koretsune
    Mariko Kajikawa
    Masaharu Kato
    Hitoshi Ueda
    Kazuma Iekushi
    Satoshi Yamanaka
    Masahiro Tajiri
    Hypertension Research, 2014, 37 : 457 - 462
  • [26] Rivaroxaban versus warfarin in Japanese patients with non-valvular atrial fibrillation in relation to hypertension: a subgroup analysis of the J-ROCKET AF trial
    Matsumoto, Masayasu
    Hori, Masatsugu
    Tanahashi, Norio
    Momomura, Shin-ichi
    Uchiyama, Shinichiro
    Goto, Shinya
    Izumi, Tohru
    Koretsune, Yukihiro
    Kajikawa, Mariko
    Kato, Masaharu
    Ueda, Hitoshi
    Iekushi, Kazuma
    Yamanaka, Satoshi
    Tajiri, Masahiro
    HYPERTENSION RESEARCH, 2014, 37 (05) : 457 - 462
  • [27] Outcomes of Discontinuing Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation Analysis From the ROCKET AF Trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation)
    Patel, Manesh R.
    Hellkamp, Anne S.
    Lokhnygina, Yuliya
    Piccini, Jonathan P.
    Zhang, Zhongxin
    Mohanty, Surya
    Singer, Daniel E.
    Hacke, Werner
    Breithardt, Guenter
    Halperin, Jonathan L.
    Hankey, Graeme J.
    Becker, Richard C.
    Nessel, Christopher C.
    Berkowitz, Scott D.
    Califf, Robert M.
    Fox, Keith A. A.
    Mahaffey, Kenneth W.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 61 (06) : 651 - 658
  • [28] Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)
    Halperin, Jonathan L.
    Hankey, Graeme J.
    Wojdyla, Daniel M.
    Piccini, Jonathan P.
    Lokhnygina, Yuliya
    Patel, Manesh R.
    Breithardt, Guenter
    Singer, Daniel E.
    Becker, Richard C.
    Hacke, Werner
    Paolini, John F.
    Nessel, Christopher C.
    Mahaffey, Kenneth W.
    Califf, Robert M.
    Fox, Keith A. A.
    CIRCULATION, 2014, 130 (02) : 138 - U45
  • [29] Rivaroxaban in the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Clinical Implications of the ROCKET AF Trial and Its Subanalyses
    Ryan J. Spencer
    John V. Amerena
    American Journal of Cardiovascular Drugs, 2015, 15 : 395 - 401
  • [30] Rivaroxaban in the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Clinical Implications of the ROCKET AF Trial and Its Subanalyses
    Spencer, Ryan J.
    Amerena, John V.
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2015, 15 (06) : 395 - 401
12345